Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2024 10:38 ET | Source: OrphAI Therapeutics Inc.

OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union

GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
September 28, 2023 11:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Name Change to OrphAI Therapeutics

GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
August 31, 2023 10:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)

GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
July 24, 2023 07:19 ET | Source: KuicK Research

US FDA Approved Orphan Drugs Market Size Drugs Sales Insight

Delhi, July 24, 2023 (GLOBE NEWSWIRE) -- US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028 Report Highlights: US Orphan Drugs Market Opportunity: > USD 150...
July 12, 2023 11:45 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Appointment of Biotechnology Industry Leader David Scheer as Chairman of the Board of Directors

GUILFORD, Conn., July 12, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment...